Matinas BioPharma's market cap is currently $2.96M. The company's EPS TTM is $-4.558; its P/E ratio is ―; Matinas BioPharma is scheduled to report earnings on March 18, 2025, and the estimated EPS forecast is $-0.78. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 1.10M	$ 3.19M	$ 33.33K	$ 158.33K	$ 90.00K
Gross Profit	$ -13.39M	$ -13.49M	$ -748.16K	$ -14.20M	$ -11.14M
Operating Income	$ -23.77M	$ -24.59M	$ -24.73M	$ -24.21M	$ -18.92M
EBITDA	$ -22.82M	$ -24.23M	$ -24.45M	$ -23.92M	$ -18.59M
Net Income	$ -22.94M	$ -13.02M	$ -21.17M	$ -20.60M	$ -15.59M
Balance Sheet
Cash & Short-Term Investments	$ 13.76M	$ 28.76M	$ 49.62M	$ 58.68M	$ 27.77M
Total Assets	$ 25.10M	$ 44.82M	$ 61.33M	$ 70.97M	$ 40.24M
Total Debt	$ 3.56M	$ 4.12M	$ 4.70M	$ 3.75M	$ 4.23M
Net Debt	$ -1.23M	$ -2.71M	$ -16.33M	$ -8.68M	$ -17.94M
Total Liabilities	$ 5.86M	$ 8.18M	$ 8.83M	$ 7.24M	$ 7.19M
Stockholders' Equity	$ 19.25M	$ 36.64M	$ 52.49M	$ 63.73M	$ 33.05M
Cash Flow
Free Cash Flow	$ -15.50M	$ -20.05M	$ -15.48M	$ -17.37M	$ -14.50M
Operating Cash Flow	$ -15.28M	$ -19.16M	$ -15.22M	$ -17.37M	$ -14.09M
Investing Cash Flow	$ 13.24M	$ 4.88M	$ 16.77M	$ -40.67M	$ -6.01M
Financing Cash Flow	$ -7.00K	$ 79.00K	$ 6.96M	$ 48.05M	$ 29.85M

Currency in USD

Matinas BioPharma Earnings and Revenue History

Income Statement >

Matinas BioPharma Debt to Assets

Balance Sheet >

Matinas BioPharma Cash Flow

Cash Flow >

Matinas BioPharma Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing